Sacubitril/Valsartan for CKD5 Stage Dialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

March 1, 2023

Study Completion Date

March 8, 2023

Conditions
CKD5 Stage DialysisHeart Failure
Interventions
DRUG

Sacubitril/Valsartan

The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).

DRUG

Irbesartan

The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.

Trial Locations (1)

Unknown

Department of Nephrology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT05243199 - Sacubitril/Valsartan for CKD5 Stage Dialysis Patients | Biotech Hunter | Biotech Hunter